



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

January 2022





© 2022 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

January 2022

N = 7470



Health Authority	Male	Female	All
FRASER	1466	453	1919
INTERIOR	447	111	558
NORTHERN	143	78	221
VANCOUVER COASTAL	3319	450	3769
VANCOUVER ISLAND	798	161	959
	6173	1253	7426
		Unknown/not stated:	44
		Total:	7470

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (January 2017 - January 2022)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (January 2017 - January 2022)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (January 2017 - January 2022)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (January 2017 - January 2022)






1.6 Percent Distribution of Active Participants by CD4 Count (January 2017 - January 2022)






1.7 Percent Distribution of Inactive Participants by CD4 Count (January 2017 - January 2022)






1.8 Active and Inactive Participants (January 2017 - January 2022)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (January 2017 - January 2022)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (January 2017 - January 2022)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(January 2017 - January 2022)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (January 2017 - January 2022)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(January 2017 - January 2022)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (January 2017 - January 2022)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT (January 2017 - January 2022)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (January 2017 - January 2022)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(January 2017 - January 2022)






1.18 Baseline CD4 for Antiretroviral First Starts
(January 2017 - January 2022)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (January 2017 - January 2022)






1.20 Cumulative Resistance Testing Results by Resistance Category (January 2017 - January 2022)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (January 2017 - January 2022)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2022
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	29	5	0	5	2	585	5	<40	4
1988	31	5	0	5	3	660	5	<40	3
1989	29	51	1	52	27	510	48	<40	3
1990	27	55	1	56	33	550	55	<40	3
1991	28	36	3	39	18	565	35	<40	3
1992	27	53	5	58	27	590	54	<40	3
1993	26	124	14	138	85	530	127	<40	3
1994	25	73	12	85	54	540	81	<40	3
1995	25	125	20	145	98	585	139	<40	3
1996	23	311	46	357	226	565	340	<40	3
1997	21	266	31	297	189	630	271	<40	3
1998	20	189	40	229	140	555	207	<40	3
1999	20	151	39	190	115	550	171	<40	3
2000	21	115	28	143	89	640	130	<40	3
2001	20	116	26	142	85	600	122	<40	3
2002	19	122	25	147	94	580	131	<40	3
2003	18	141	26	167	94	615	154	<40	3
2004	17	149	40	189	131	610	169	<40	3
2005	16	179	44	223	152	659	197	<40	3
2006	15	166	42	208	128	630	184	<40	3
2007	14	230	46	276	185	640	243	<40	3
2008	13	279	64	343	236	650	309	<40	3
2009	12	302	65	367	241	660	334	<40	3
2010	11	266	67	333	222	675	296	<40	3
2011	10	319	72	391	253	710	348	<40	3
2012	9	268	64	332	216	700	291	<40	3
2013	8	252	60	312	206	700	275	<40	3
2014	7	264	48	312	195	700	286	<40	3
2015	6	269	44	313	207	720	277	<40	3
2016	5	255	54	309	194	650	275	<40	3
2017	5	214	33	247	170	655	222	<40	3
2018	4	188	56	244	164	710	220	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2022
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
2019	3	232	40	272	201	670	257	<40	3
2020	2	192	54	246	178	705	221	<40	3
2021	1	214	44	258	194	580	242	<40	3
2022	0	11	4	15	13	500	15	<40	3
Total:		6187	1258	7445					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2021	7384	746	1942	<40	1391	630
FEB-2021	7377	748	1787	<40	1273	630
MAR-2021	7432	743	2016	<40	1426	620
APR-2021	7417	746	1828	<40	1322	633
MAY-2021	7452	742	1868	<40	1304	630
JUN-2021	7456	738	1880	<40	1352	610
JUL-2021	7460	744	1820	<40	1343	640
AUG-2021	7466	741	1981	<40	1346	630
SEP-2021	7432	750	1762	<40	1235	630
OCT-2021	7431	755	1855	<40	1275	630
NOV-2021	7446	750	2020	<40	1340	630
DEC-2021	7466	757	1544	<40	986	630
JAN-2022	7470	756	1879	<40	1208	650

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2021	783	202	73	<40	57	510
FEB-2021	795	199	69	<40	56	510
MAR-2021	780	251	89	<40	70	630
APR-2021	813	258	73	<40	58	615
MAY-2021	792	276	73	<40	65	530
JUN-2021	791	272	65	57	48	535
JUL-2021	794	278	52	102	37	530
AUG-2021	800	273	53	<40	40	645
SEP-2021	844	230	64	<40	41	610
OCT-2021	847	245	78	<40	60	540
NOV-2021	831	270	79	<40	59	450
DEC-2021	808	271	46	<40	29	360
JAN-2022	800	287	54	<40	38	555

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2021	7360	783	14	9	205	160	37	14211
FEB-2021	7353	795	15	13	186	189	-7	14235
MAR-2021	7407	780	15	24	203	156	54	14272
APR-2021	7393	813	13	9	165	172	-14	14297
MAY-2021	7421	792	14	14	177	143	28	14326
JUN-2021	7438	791	7	15	186	175	17	14352
JUL-2021	7439	794	9	12	170	168	1	14372
AUG-2021	7438	800	16	12	174	167	-1	14394
SEP-2021	7401	844	14	9	173	199	-37	14424
OCT-2021	7393	847	17	6	185	174	-8	14447
NOV-2021	7420	831	11	15	199	175	27	14473
DEC-2021	7438	808	21	6	205	172	18	14491
JAN-2022	7445	800	15	7	161	143	7	14506

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2021	205	6681	452	46	7384	2.78%	90.48%	6.12%	0.62%	100.00%
FEB-2021	226	6652	448	51	7377	3.06%	90.17%	6.07%	0.69%	100.00%
MAR-2021	249	6669	463	51	7432	3.35%	89.73%	6.23%	0.69%	100.00%
APR-2021	275	6644	454	44	7417	3.71%	89.58%	6.12%	0.59%	100.00%
MAY-2021	299	6640	465	48	7452	4.01%	89.10%	6.24%	0.64%	100.00%
JUN-2021	326	6613	471	46	7456	4.37%	88.69%	6.32%	0.62%	100.00%
JUL-2021	354	6590	470	46	7460	4.75%	88.34%	6.30%	0.62%	100.00%
AUG-2021	381	6572	471	42	7466	5.10%	88.03%	6.31%	0.56%	100.00%
SEP-2021	398	6525	462	47	7432	5.36%	87.80%	6.22%	0.63%	100.00%
OCT-2021	409	6516	460	46	7431	5.50%	87.69%	6.19%	0.62%	100.00%
NOV-2021	438	6508	457	43	7446	5.88%	87.40%	6.14%	0.58%	100.00%
DEC-2021	468	6496	457	45	7466	6.27%	87.01%	6.12%	0.60%	100.00%
JAN-2022	500	6473	455	42	7470	6.69%	86.65%	6.09%	0.56%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	2 10%	3153 44%	1 5%	2880 40%	0 0%	28 0%	12 60%	2220 31%	6 30%	1962 27%	18 90%	4045 56%
FEB-2021	2 8%	3135 43%	2 8%	2843 39%	0 0%	27 0%	16 67%	2298 32%	6 25%	1899 26%	22 92%	4061 56%
MAR-2021	8 22%	3140 43%	7 19%	2832 39%	0 0%	24 0%	23 62%	2368 33%	6 16%	1858 26%	29 78%	4111 57%
APR-2021	2 8%	3137 43%	2 8%	2802 39%	0 0%	25 0%	17 68%	2422 33%	6 24%	1791 25%	23 92%	4104 57%
MAY-2021	7 24%	3150 43%	3 10%	2784 38%	0 0%	22 0%	15 52%	2497 34%	10 34%	1759 24%	22 76%	4131 57%
JUN-2021	4 15%	3137 43%	3 12%	2741 38%	0 0%	23 0%	17 65%	2574 35%	5 19%	1698 23%	22 85%	4153 57%
JUL-2021	3 15%	3126 43%	2 10%	2707 37%	0 0%	23 0%	13 65%	2626 36%	4 20%	1655 23%	17 85%	4166 57%
AUG-2021	1 5%	3109 43%	1 5%	2667 37%	0 0%	23 0%	16 73%	2661 36%	5 23%	1631 22%	21 95%	4183 57%
SEP-2021	4 13%	3078 42%	2 7%	2614 36%	1 3%	22 0%	21 70%	2707 37%	5 17%	1587 22%	26 87%	4178 57%
OCT-2021	5 22%	3081 42%	5 22%	2590 36%	0 0%	20 0%	13 57%	2755 38%	5 22%	1563 21%	18 78%	4196 58%
NOV-2021	3 12%	3070 42%	2 8%	2551 35%	0 0%	19 0%	18 72%	2813 39%	4 16%	1534 21%	22 88%	4217 58%
DEC-2021	3 18%	3070 42%	1 6%	2516 34%	0 0%	19 0%	10 59%	2862 39%	5 29%	1505 21%	14 82%	4239 58%
JAN-2022	3 20%	3068 42%	3 20%	2483 34%	0 0%	19 0%	12 80%	2923 40%	0 0%	1473 20%	12 80%	4264 58%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		saquinavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	0 0%	1 0%	0 0%	655 32%	5 100%	1297 64%	0 0%	71 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2021	0 0%	1 0%	0 0%	643 33%	5 100%	1262 64%	0 0%	71 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
MAR-2021	0 0%	1 0%	1 25%	621 32%	3 75%	1261 65%	0 0%	73 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
APR-2021	0 0%	1 0%	0 0%	595 31%	4 100%	1230 65%	0 0%	72 4%	0 0%	1 0%	0 0%	2 0%	0 0%	1 0%
MAY-2021	0 0%	1 0%	0 0%	589 31%	4 100%	1239 65%	0 0%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUN-2021	0 0%	1 0%	0 0%	573 31%	4 80%	1221 66%	1 20%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUL-2021	0 0%	1 0%	0 0%	560 30%	6 100%	1216 66%	0 0%	68 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
AUG-2021	0 0%	0 0%	0 0%	547 30%	2 100%	1205 66%	0 0%	66 4%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%
SEP-2021	0 0%	1 0%	0 0%	536 30%	2 100%	1184 66%	0 0%	61 3%	0 0%	2 0%	0 0%	0 0%	0 0%	1 0%
OCT-2021	0 0%	1 0%	0 0%	515 29%	3 100%	1182 67%	0 0%	59 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
NOV-2021	0 0%	1 0%	0 0%	508 29%	3 75%	1170 68%	1 25%	58 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
DEC-2021	0 0%	1 0%	0 0%	492 29%	2 100%	1152 68%	0 0%	58 3%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%
JAN-2022	0 0%	1 0%	0 0%	476 29%	0 0%	1132 68%	0 0%	60 4%	0 0%	1 0%	0 0%	0 0%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	0 0%	11 1%	1 100%	426 34%	0 0%	164 13%	0 0%	379 30%	0 0%	272 22%
FEB-2021	0 0%	15 1%	0 0%	418 34%	0 0%	161 13%	0 0%	365 30%	0 0%	267 22%
MAR-2021	0 0%	21 2%	2 100%	419 34%	0 0%	162 13%	0 0%	365 30%	0 0%	266 22%
APR-2021	0 0%	20 2%	1 50%	409 34%	0 0%	155 13%	1 50%	359 30%	0 0%	260 22%
MAY-2021	1 20%	30 3%	3 60%	397 33%	0 0%	154 13%	0 0%	353 30%	1 20%	259 22%
JUN-2021	0 0%	41 4%	2 100%	379 32%	0 0%	155 13%	0 0%	345 30%	0 0%	251 22%
JUL-2021	0 0%	45 4%	1 100%	371 32%	0 0%	153 13%	0 0%	339 29%	0 0%	243 21%
AUG-2021	0 0%	56 5%	1 100%	366 32%	0 0%	150 13%	0 0%	337 29%	0 0%	241 21%
SEP-2021	0 0%	67 6%	3 75%	357 31%	0 0%	146 13%	0 0%	332 29%	1 25%	242 21%
OCT-2021	1 14%	81 7%	1 14%	350 31%	1 14%	142 12%	1 14%	326 29%	3 43%	244 21%
NOV-2021	0 0%	92 8%	1 33%	346 30%	0 0%	142 13%	0 0%	318 28%	2 67%	244 21%
DEC-2021	0 0%	99 9%	3 75%	340 30%	0 0%	134 12%	0 0%	317 28%	1 25%	243 21%
JAN-2022	0 0%	104 9%	0 0%	327 29%	0 0%	130 12%	0 0%	317 29%	0 0%	235 21%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2021	12 80%	1697 34%	3 20%	2461 49%	0 0%	442 9%	0 0%	27 1%	0 0%	469 9%
FEB-2021	14 64%	1774 35%	5 23%	2476 49%	3 14%	420 8%	0 0%	24 0%	0 0%	457 9%
MAR-2021	23 72%	1839 35%	9 28%	2491 48%	0 0%	418 8%	0 0%	24 0%	0 0%	454 9%
APR-2021	15 75%	1901 36%	4 20%	2504 48%	1 5%	412 8%	0 0%	22 0%	0 0%	438 8%
MAY-2021	15 65%	1979 37%	7 30%	2509 47%	0 0%	397 7%	0 0%	22 0%	1 4%	439 8%
JUN-2021	16 76%	2056 38%	4 19%	2498 47%	1 5%	387 7%	0 0%	23 0%	0 0%	440 8%
JUL-2021	13 81%	2111 39%	3 19%	2498 46%	0 0%	382 7%	0 0%	23 0%	0 0%	432 8%
AUG-2021	15 71%	2151 40%	5 24%	2488 46%	1 5%	374 7%	0 0%	23 0%	0 0%	424 8%
SEP-2021	18 72%	2193 40%	5 20%	2470 46%	2 8%	365 7%	0 0%	23 0%	0 0%	411 8%
OCT-2021	11 73%	2235 41%	3 20%	2469 45%	1 7%	362 7%	0 0%	24 0%	0 0%	398 7%
NOV-2021	17 77%	2305 42%	4 18%	2459 45%	1 5%	347 6%	0 0%	24 0%	0 0%	392 7%
DEC-2021	8 57%	2350 42%	5 36%	2465 45%	1 7%	348 6%	0 0%	24 0%	0 0%	380 7%
JAN-2022	11 73%	2422 43%	2 13%	2472 44%	1 7%	347 6%	0 0%	24 0%	1 7%	374 7%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		3 drugs from 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2021	1273	17.24	912	12.35	4191	56.76	202	2.74	693	9.39	113	1.53
FEB-2021	1232	16.70	894	12.12	4226	57.29	223	3.02	689	9.34	113	1.53
MAR-2021	1209	16.27	890	11.98	4274	57.51	246	3.31	707	9.51	106	1.43
APR-2021	1166	15.72	868	11.70	4319	58.23	273	3.68	690	9.30	101	1.36
MAY-2021	1146	15.38	858	11.51	4348	58.35	296	3.97	704	9.45	100	1.34
JUN-2021	1125	15.09	834	11.19	4370	58.61	324	4.35	705	9.46	98	1.31
JUL-2021	1104	14.80	820	10.99	4383	58.75	352	4.72	702	9.41	99	1.33
AUG-2021	1090	14.60	817	10.94	4385	58.73	377	5.05	700	9.38	97	1.30
SEP-2021	1070	14.40	812	10.93	4370	58.80	394	5.30	694	9.34	92	1.24
OCT-2021	1052	14.16	809	10.89	4387	59.04	406	5.46	685	9.22	92	1.24
NOV-2021	1037	13.93	804	10.80	4397	59.05	435	5.84	682	9.16	91	1.22
DEC-2021	1020	13.66	792	10.61	4418	59.17	464	6.21	682	9.13	90	1.21
JAN-2022	985	13.19	773	10.35	4457	59.67	497	6.65	672	9.00	86	1.15

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2021	9	1	3	0	1	2	170
FEB-2021	13	0	2	3	4	4	360
MAR-2021	24	4	5	3	5	5	280
APR-2021	9	2	1	1	1	4	370
MAY-2021	14	1	1	3	2	4	480
JUN-2021	15	4	1	3	2	4	289
JUL-2021	12	1	2	0	2	4	480
AUG-2021	12	1	1	4	2	2	300
SEP-2021	9	0	1	2	2	3	400
OCT-2021	6	1	0	1	0	2	490
NOV-2021	15	3	2	2	2	3	260
DEC-2021	6	1	1	1	3	0	350
JAN-2022	7	1	0	1	1	3	490

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2021	12389	3839
FEB-2021	12382	3834
MAR-2021	12380	3823
APR-2021	12369	3810
MAY-2021	12364	3798
JUN-2021	12365	3792
JUL-2021	12386	3811
AUG-2021	12380	3817
SEP-2021	12349	3786
OCT-2021	12336	3778
NOV-2021	12339	3769
DEC-2021	12321	3764
JAN-2022	12311	3763

Definitions:


Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7470
Jan-2022

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jan-2022

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jan-2022

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jan-2022

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jan-2022

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	7	7	*
	35-49	11	12	*
	50+	26	40	*
	Total HSDA:	44	59	30
KOOTENAY BOUNDARY	0-19	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	73	100	58
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	410	553	314
THOMPSON/CARIBOO/ SHUSWAP	20-34	20	20	10
	35-49	68	73	49
	50+	120	193	97
	Total HSDA:	208	286	156
Total HA:		735	998	558

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		735	998	558

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	146	200	111
Male	589	798	447

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	558	56	620	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	22	13
	5 years or more	12	9
	<5 years	10	8
	Total HSDA:	44	30
KOOTENAY BOUNDARY	10 years or more	46	35
	5 years or more	15	11
	<5 years	12	12
	Total HSDA:	73	58
OKANAGAN	10 years or more	266	197
	5 years or more	92	74
	<5 years	52	43
	Total HSDA:	410	314
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	132	102
	5 years or more	45	33
	<5 years	31	21
	Total HSDA:	208	156
Total HA:		735	558

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	466	347
	5 years or more	164	127
	<5 years	105	84
Total HA:		735	558

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	51	70	13	28
KOOTENAY BOUNDARY	77	133	25	54
OKANAGAN	231	979	52	298
THOMPSON/CARIBOO/SHUSWAP	143	539	34	135
Total:	502	1721	124	515

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	110

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	7
	20-34	34	36	28
	35-49	95	101	62
	50+	245	340	184
	Total HSDA:	381	484	281
FRASER NORTH	20-34	122	122	81
	35-49	347	373	261
	50+	626	989	481
	Total HSDA:	1095	1484	823
FRASER SOUTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1017	1349	815
Total HA:		2493	3317	1919

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	11	11	11
	20-34	265	269	182
	35-49	742	807	561
	50+	1475	2230	1165
Total HA:		2493	3317	1919

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	606	774	453
Male	1887	2543	1466

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1919	53	650	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	237	175
	5 years or more	78	54
	<5 years	66	52
	Total HSDA:	381	281
FRASER NORTH	10 years or more	674	485
	5 years or more	237	187
	<5 years	184	151
	Total HSDA:	1095	823
FRASER SOUTH	10 years or more	618	491
	5 years or more	234	184
	<5 years	165	140
	Total HSDA:	1017	815
Total HA:		2493	1919

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1529	1151
	5 years or more	549	425
	<5 years	415	343
Total HA:		2493	1919

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	142	518	31	58
FRASER NORTH	256	1624	45	221
FRASER SOUTH	225	1669	52	480
Total:	623	3811	128	759

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	185
FRASER NORTH	686
FRASER SOUTH	459
Total:	1330

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		358	517
RICHMOND	20-34	32	33	17
	35-49	48	50	39
	50+	108	160	89
	Total HSDA:	188	243	145
VANCOUVER	0-19	11	11	9
	20-34	427	444	278
	35-49	1266	1418	912
	50+	2935	5151	2133
	Total HSDA:	4639	7024	3332
Total HA:		5185	7784	3769

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	10
	20-34	491	509	319
	35-49	1401	1563	1014
	50+	3281	5700	2426
Total HA:		5185	7784	3769

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	605	954	450
Male	4578	6828	3319
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3769	55	650	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	219	178
	5 years or more	76	62
	<5 years	63	52
	Total HSDA:	358	292
RICHMOND	10 years or more	113	87
	5 years or more	33	23
	<5 years	42	35
	Total HSDA:	188	145
VANCOUVER	10 years or more	3122	2171
	5 years or more	904	672
	<5 years	613	489
	Total HSDA:	4639	3332
Total HA:		5185	3769

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3454	2436
	5 years or more	1013	757
	<5 years	718	576
Total HA:		5185	3769

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	184	410	56	81
RICHMOND	44	299	8	92
VANCOUVER	658	11247	216	5348
Total:	886	11956	280	5521

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	79

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		344	500
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		121	169
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		776	1109
Total HA:		1241	1778	959

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	5
	20-34	115	125	78
	35-49	287	332	226
	50+	833	1315	650
Total HA:		1241	1778	959

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	215	311	161
Male	1026	1467	798

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	959	55	590	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	208	169
	5 years or more	79	58
	<5 years	57	45
	Total HSDA:	344	272
NORTH VANCOUVER ISLAND	10 years or more	81	65
	5 years or more	28	16
	<5 years	12	12
	Total HSDA:	121	93
SOUTH VANCOUVER ISLAND	10 years or more	466	329
	5 years or more	158	132
	<5 years	152	133
	Total HSDA:	776	594
Total HA:		1241	959

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	755	563
	5 years or more	265	206
	<5 years	221	190
Total HA:		1241	959

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribers in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	203	908	74	196
NORTH VANCOUVER ISLAND	154	274	40	68
SOUTH VANCOUVER ISLAND	220	1883	42	573
Total:	577	3065	156	837

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	58
NORTH VANCOUVER ISLAND	43
SOUTH VANCOUVER ISLAND	128
Total:	229

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	46	57	23
NORTH WEST	20-34	*	6	0
	35-49	*	40	21
	50+	*	73	37
	Total HSDA:	72	119	58
NORTHERN INTERIOR	0-19	6	6	*
	20-34	21	23	*
	35-49	55	70	*
	50+	112	186	*
	Total HSDA:	194	285	140
Total HA:		312	461	221

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	29	33	*
	35-49	99	132	*
	50+	178	290	*
Total HA:		312	461	221

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	117	173	78
Male	195	288	143

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	221	53	590	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	29	*
	5 years or more	6	*
	<5 years	11	*
	Total HSDA:	46	23
NORTH WEST	10 years or more	47	37
	5 years or more	14	12
	<5 years	11	9
	Total HSDA:	72	58
NORTHERN INTERIOR	10 years or more	96	73
	5 years or more	62	41
	<5 years	36	26
	Total HSDA:	194	140
Total HA:		312	221

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	172	123
	5 years or more	82	55
	<5 years	58	43
Total HA:		312	221

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	39	61	4	*
NORTH WEST	82	167	19	*
NORTHERN INTERIOR	118	486	19	*
Total:	239	714	42	233

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	6
NORTH WEST	21
NORTHERN INTERIOR	13
Total:	40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	5	11	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	27	45	19
	THOMPSON/CARIBOO/SHUSWAP	26	50	20
	Total HA:	64	115	50
FRASER	FRASER EAST	34	47	25
	FRASER NORTH	54	93	42
	FRASER SOUTH	85	119	64
	Total HA:	173	259	131
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	30	53	27
	RICHMOND	7	12	6
	VANCOUVER	464	890	375
	Total HA:	501	955	408
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	47	81	36
	NORTH VANCOUVER ISLAND	13	25	9
	SOUTH VANCOUVER ISLAND	43	88	35
	Total HA:	103	194	80
NORTHERN	NORTH EAST	11	15	6
	NORTH WEST	32	67	27
	NORTHERN INTERIOR	67	110	50
	Total HA:	110	192	83
Total:		951	1715	752

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	350	614	277
Male	601	1101	475

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	752	53	520	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Antiretroviral: a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla: the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Descovy: the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.





Monthly Report

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir: an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine: a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.





Monthly Report

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.





Monthly Report

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

